Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MGN-3

This article was originally published in The Tan Sheet

Executive Summary

Lane Labs supplement has "direct effect" on "tumor cell growth and cytokine production," in addition to previous findings showing agent enhances natural killer cell activity, according to a poster presented by Mamdooh Ghoneum, PhD, Charles Drew University and UCLA, et al., at American Association for Cancer Research annual meeting in New Orleans March 24-28. Lane Lab's Internet promotions for MGN-3, "a patented, Japanese compound consisting of hydrolyzed rice bran extracts modified by Shiitake mushroom enzymes," caused FDA and FTC to charge product is an unapproved drug. While FTC charges have been settled, FDA negotiations are ongoing, Lane Labs notes
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel